EyePoint Pharmaceuticals

CompanyUnited States

EyePoint Pharmaceuticals develops 2 assets, the furthest approved (dexamethasone in burns). Mostly small molecule acting on NF-κB signalling, apoptosis and NR3C1; based in the United States.

Assets
2
Furthest
Approved
Trials
3
Signals
0

Pipeline

2

  • dexamethasone

    Glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive effects

    ApprovedSmall moleculeNF-κB signallingApoptosisburnsConjunctivitis, Allergic

  • EYP-1901

    Tyrosine kinase inhibitor formulation delivering sustained-release vorolanib to inhibit VEGFR/PDGFR signaling

    Phase 3Small moleculeFLT1PDGFRBdiabetic macular edemaDME

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms7
  • Trials3
  • Signals3
  • Similar companies6

Updated 7 Oct 2026 · 62 sources

Intelligence